Recursion Announces 10th Site Open for REC-994 Trial

August 12, 2022 –Recursion Pharmaceuticals has ten US sites enrolling cavernous malformation patients in Phase 2 of their REC-994 Sycamore trial. This is the first industry-sponsored trial of a medicine for cerebral cavernous malformations, a massive milestone toward better treatments.

The ninth site to open is Valley Hospital in Ridgewood, New Jersey, under the direction of Dr. Dorothea Altshul.  The 10th site is Columbia Presbyterian Hospital, under the direction of Dr. Sander Connolly.  Please visit our website’s REC-994 Trial Information page for the complete list of open enrollment sites and inclusion/exclusion criteria.